EE05496B1 - Antikeha, mis seob osteoprotegeriini siduvat valku - Google Patents

Antikeha, mis seob osteoprotegeriini siduvat valku

Info

Publication number: EE05496B1
Authority: EE; Estonia
Prior art keywords: binding protein; binds; antibody; fragments; encoding
Prior art date: 1997-04-16

Application number

EEP199900611A

Other languages

English (en)

Estonian (et)

Inventor

J. Boyle William

Original Assignee

Amgen Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-16

Filing date

1998-04-15

Publication date

2011-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27368158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05496(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-04-16 Priority claimed from US08/842,842 external-priority patent/US5843678A/en

1998-03-30 Priority claimed from US09/052,521 external-priority patent/US6316408B1/en

1998-04-15 Application filed by Amgen Inc. filed Critical Amgen Inc.

2000-08-15 Publication of EE9900611A publication Critical patent/EE9900611A/xx

2011-12-15 Publication of EE05496B1 publication Critical patent/EE05496B1/xx

Links

108091008324 binding proteins Proteins 0.000 title abstract 2
102000008108 Osteoprotegerin Human genes 0.000 title 1
108010035042 Osteoprotegerin Proteins 0.000 title 1
102000023732 binding proteins Human genes 0.000 title 1
XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 title 1
239000012634 fragment Substances 0.000 abstract 3
150000007523 nucleic acids Chemical class 0.000 abstract 3
102000039446 nucleic acids Human genes 0.000 abstract 2
108020004707 nucleic acids Proteins 0.000 abstract 2
208000020084 Bone disease Diseases 0.000 abstract 1
102000014914 Carrier Proteins Human genes 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
230000004069 differentiation Effects 0.000 abstract 1
239000013604 expression vector Substances 0.000 abstract 1
210000002997 osteoclast Anatomy 0.000 abstract 1
239000013598 vector Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Immunology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Steroid Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EEP199900611A 1997-04-16 1998-04-15 Antikeha, mis seob osteoprotegeriini siduvat valku EE05496B1 (et)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US08/842,842 US5843678A (en)	1997-04-16	1997-04-16	Osteoprotegerin binding proteins
US88085597A	1997-06-23	1997-06-23
US09/052,521 US6316408B1 (en)	1997-04-16	1998-03-30	Methods of use for osetoprotegerin binding protein receptors
PCT/US1998/007584 WO1998046751A1 (en)	1997-04-16	1998-04-15	Osteoprotegerin binding proteins and receptors

Publications (2)

Publication Number	Publication Date
EE9900611A EE9900611A (et)	2000-08-15
EE05496B1 true EE05496B1 (et)	2011-12-15

Family

ID=27368158

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP199900611A EE05496B1 (et)	1997-04-16	1998-04-15	Antikeha, mis seob osteoprotegeriini siduvat valku

Country Status (27)

Country	Link
US (1)	US7923008B2 (de)
EP (2)	EP1717315A3 (de)
JP (2)	JP2001526532A (de)
CN (1)	CN1264427A (de)
AT (1)	ATE363533T1 (de)
AU (4)	AU743257B2 (de)
BG (1)	BG65242B1 (de)
BR (1)	BR9808545A (de)
CA (1)	CA2285746C (de)
CZ (1)	CZ302262B6 (de)
DE (1)	DE69837845T3 (de)
DK (1)	DK0975754T4 (de)
EA (1)	EA003636B1 (de)
EE (1)	EE05496B1 (de)
ES (1)	ES2284203T5 (de)
HU (1)	HU230547B1 (de)
ID (1)	ID23855A (de)
IL (1)	IL132304A0 (de)
NO (1)	NO325175B1 (de)
NZ (1)	NZ500253A (de)
PL (1)	PL190092B1 (de)
RO (1)	RO128635A2 (de)
SI (1)	SI0975754T2 (de)
SK (1)	SK288559B6 (de)
TR (1)	TR199902512T2 (de)
TW (1)	TW589376B (de)
WO (1)	WO1998046751A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL117175A (en)	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
WO1998025958A2 (en) *	1996-12-13	1998-06-18	Schering Corporation	Mammalian cell surface antigens comprising structural motifs characteristic of a member of the tnf ligand family
EP2003203A1 (de)	1996-12-23	2008-12-17	Immunex Corporation	Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist
US6271349B1 (en)	1996-12-23	2001-08-07	Immunex Corporation	Receptor activator of NF-κB
AU2008200700C1 (en) *	1997-04-15	2013-04-04	Daiichi Sankyo Co., Ltd	Novel Protein and Process for Producing The Same
EP2336168A1 (de)	1997-04-15	2011-06-22	Sankyo Company Limited	Neues Protein und Methoe zur Herstellung
ATE363533T1 (de)	1997-04-16	2007-06-15	Amgen Inc	Osteoprotegerin bindende proteine und rezeptoren
US6316408B1 (en)	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
ATE412746T1 (de) *	1998-05-14	2008-11-15	Immunex Corp	Verfahren zur hemmung der wirkung der osteoklasten
US20020106728A1 (en) *	2000-06-20	2002-08-08	Genentech, Inc.	NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
SI1114166T1 (en) *	1998-09-15	2005-10-31	Pharmexa A/S	Method for down-regulating osteoprotegerin ligand activity
CN1318105A (zh)	1998-09-15	2001-10-17	M&E生物技术公司	负调节Osteoprotegerin配体活性的方法
DK2319928T3 (da)	1998-10-23	2013-06-24	Kirin Amgen Inc	Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
ES2392392T3 (es)	1999-06-28	2012-12-10	Genentech, Inc.	Métodos para producir ligando Apo-2 utilizando iones metálicos divalentes
KR20090016772A (ko)	1999-08-17	2009-02-17	바이오겐 아이덱 엠에이 인코포레이티드	Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
AU7615600A (en) *	1999-09-27	2001-04-30	Eli Lilly And Company	Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) *	1999-09-29	1999-10-21	University Of Western Australia, The	Bone cell factor
JP5062606B2 (ja)	2000-02-16	2012-10-31	ジェネンテック，インコーポレイテッド	Ｔｎｆ関連分子の活性を調節するためのアゴニスト及びアンタゴニストの使用
DE60134459D1 (de) †	2000-02-23	2008-07-31	Amgen Inc	Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
US20030103978A1 (en) *	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
US6600018B1 (en)	2000-04-10	2003-07-29	The United States Of America As Represented By The Department Of Health And Human Services	Secreted frizzled related protein, sFRP, fragments and methods of use thereof
ES2637801T3 (es)	2000-04-11	2017-10-17	Genentech, Inc.	Anticuerpos multivalentes y usos de los mismos
WO2002009755A2 (en)	2000-07-27	2002-02-07	Genentech, Inc.	Apo-2l receptor agonist and cpt-11 synergism
US20040247596A1 (en) *	2000-08-18	2004-12-09	Odgren Paul R.	TRANCE regulation of chondrocyte differentiation
WO2002024896A2 (en)	2000-09-22	2002-03-28	Immunex Corporation	Screening assays for agonists or antagonists of receptor activat or of nf-kb
JP4029041B2 (ja)	2001-01-10	2008-01-09	アメリカ合衆国	ｓＦＲＰおよびｓＦＲＰと相互作用するペプチドモチーフならびにそれらの使用法
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
MY143582A (en)	2001-06-26	2011-05-31	Amgent Fremont Inc	Antibodies to opgl
CA2451680C (en)	2001-07-03	2011-04-19	Genentech, Inc.	Human dr4 antibodies and uses thereof
CA2461292A1 (en)	2001-10-02	2003-04-10	Genentech, Inc.	Apo-2 ligand variants and uses thereof
US7842668B1 (en)	2001-11-13	2010-11-30	Genentech, Inc.	Apo-2 ligand/trail formulations
DE60237841D1 (de)	2001-11-13	2010-11-11	Genentech Inc	Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
US7741285B2 (en)	2001-11-13	2010-06-22	Genentech, Inc.	APO-2 ligand/trail formulations
AU2011265413B2 (en) *	2002-04-05	2014-04-10	Amgen Inc.	Human Anti-OPGL Neutralizing Antibodies as Selective OPGL, Pathway Inhibitors
PL375041A1 (en)	2002-04-05	2005-11-14	Amgen Inc.	Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
JP4574350B2 (ja)	2002-06-24	2010-11-04	ジェネンテック，インコーポレイテッド	Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
MXPA05006147A (es)	2002-12-10	2005-08-26	Schering Plough Ltd	Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
CA2572765C (en)	2004-07-08	2013-05-21	Amgen Inc.	Compound having improved bioefficiency when administered in a multidose regimen
RU2410438C2 (ru)	2004-08-06	2011-01-27	Дженентек, Инк.	Анализы и способы, использующие биомаркеры
CA2575152A1 (en)	2004-08-06	2006-02-16	Genentech, Inc.	Method for predicting sensitivity of mammalian cells to apo2l/trail comprising deletion of biomarker expression
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
US8029783B2 (en)	2005-02-02	2011-10-04	Genentech, Inc.	DR5 antibodies and articles of manufacture containing same
RU2409817C2 (ru)	2005-08-16	2011-01-20	Дженентек, Инк.	Анализы и способы применения биомаркеров
PE20070684A1 (es)	2005-11-14	2007-08-06	Amgen Inc	MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
AU2006318539B2 (en)	2005-11-23	2012-09-13	Genentech, Inc.	Methods and compositions related to B cell assays
US20090227032A1 (en)	2005-12-13	2009-09-10	Kyoto University	Nuclear reprogramming factor and induced pluripotent stem cells
JO3324B1 (ar)	2006-04-21	2019-03-13	Amgen Inc	مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
US8378084B2 (en) *	2006-12-22	2013-02-19	The Regents Of The University Of California	Fusion molecule based on novel TAA variant
JP5591691B2 (ja)	2007-05-22	2014-09-17	アムジエン・インコーポレーテツド	生物活性を有する融合タンパク質を作製するための組成物及び方法
JP2008307007A (ja)	2007-06-15	2008-12-25	Bayer Schering Pharma Ag	出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
EP2162747B1 (de) *	2007-06-20	2014-04-30	Galapagos N.V.	Molekulaire targets und verfahren zur identifikation von substanzen für die behandlung von degenerativen knochen- und gelenkserkrankungen
WO2009133971A1 (en) *	2008-05-02	2009-11-05	Kyoto University	Method of nuclear reprogramming
MX2011005481A (es)	2008-11-25	2011-08-17	Biogen Idec Inc	Uso de antagonistas de receptor de muerte 6 (drg6) y de p75 para promover la supervivencia de células del sistema nervioso.
EP2434285A1 (de)	2010-09-22	2012-03-28	IMBA-Institut für Molekulare Biotechnologie GmbH	Brustkrebsdiagnose
EP2433644A1 (de)	2010-09-22	2012-03-28	IMBA-Institut für Molekulare Biotechnologie GmbH	Brustkrebstherapeutika
JP2015514686A (ja)	2012-02-29	2015-05-21	コヨーテ・ファーマシューティカルズ・インコーポレイテッドＣｏｙｏｔｅＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Ｇｇａ及びそのｇｇａ誘導体組成物並びにこれらを含む麻痺状態を含めた神経変性疾患を治療する方法
US9119808B1 (en)	2012-10-08	2015-09-01	Coyote Pharmaceuticals, Inc.	Treating neurodegenerative diseases with GGA or a derivative thereof
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
US9708375B2 (en)	2013-03-15	2017-07-18	Amgen Inc.	Inhibitory polypeptides specific to WNT inhibitors
WO2015035215A1 (en)	2013-09-05	2015-03-12	Amgen Inc.	Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
US10156562B2 (en)	2014-05-16	2018-12-18	Amgen Inc.	Assay for detecting Th1 and Th2 cell populations
EP3574017A1 (de)	2017-01-27	2019-12-04	Kymab Limited	Anti-opg-antikörper
JP7672196B2 (ja)	2017-03-14	2025-05-07	アムジエン・インコーポレーテツド	細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
WO2019102380A1 (en)	2017-11-22	2019-05-31	Inbiomotion S.L.	Therapeutic treatment of breast cancer based on c-maf
KR20200135781A (ko)	2018-03-26	2020-12-03	암젠 인크	세포 배양에서 생산된 항체의 총 비푸코실화 당형태
MX2022003461A (es)	2019-09-26	2022-04-19	Amgen Inc	Metodos de produccion de composiciones de anticuerpos.
CN113621060B (zh) *	2020-05-07	2023-07-04	浙江瑞硕生物技术有限公司	一种opg抗体对及其应用
WO2021247892A1 (en)	2020-06-04	2021-12-09	Amgen Inc.	Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023004364A (es)	2020-10-15	2023-05-03	Amgen Inc	Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
AU2022289365A1 (en)	2021-06-07	2023-12-14	Amgen Inc.	Using fucosidase to control afucosylation level of glycosylated proteins
AU2022361382A1 (en)	2021-10-05	2024-03-28	Amgen Inc.	Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
AU2024256160A1 (en)	2023-04-20	2025-10-02	Amgen Inc.	Methods of determining relative unpaired glycan content
WO2025038600A1 (en)	2023-08-14	2025-02-20	Amgen Inc.	Methods for reducing yellow color
WO2025101820A1 (en)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4710457A (en)	1983-06-29	1987-12-01	Sloan-Kettering Institute For Cancer Research	Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en)	1983-08-10	1987-12-01	Amgen, Inc.	DNA plasmids
US4959314A (en)	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US6150090A (en)	1986-01-09	2000-11-21	Massachusetts Institute Of Technology	Nuclear factors associated with transcriptional regulation
US5846534A (en)	1988-02-12	1998-12-08	British Technology Group Limited	Antibodies to the antigen campath-1
CA2071912C (en)	1990-11-30	2002-10-15	Hanne Bentz	Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair
US5118667A (en)	1991-05-03	1992-06-02	Celtrix Pharmaceuticals, Inc.	Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en)	1991-05-13	1992-11-14	Masahiko Sato	Method for inhibiting bone resorption
MX9204303A (es)	1991-07-23	1993-11-01	Rhone Poulenc Rorer Int	Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en)	1991-08-07	1992-07-15	Yeda Res & Dev	Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5961974A (en)	1991-10-25	1999-10-05	Immunex Corporation	Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5447851B1 (en)	1992-04-02	1999-07-06	Univ Texas System Board Of	Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JPH07509223A (ja)	1992-04-30	1995-10-12	アムジェンインコーポレイテッド	インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
US5585479A (en)	1992-07-24	1996-12-17	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en)	1993-03-12	1996-11-26	Tam; Cherk S.	Method of increasing bone growth
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
JPH09502614A (ja)	1993-09-14	1997-03-18	メルクエンドカンパニーインコーポレーテッド	新規ヒト蛋白質チロシンホスファターゼをコードするｃＤＮＡ
US6268212B1 (en)	1993-10-18	2001-07-31	Amgen Inc.	Tissue specific transgene expression
US5641747A (en)	1994-07-25	1997-06-24	Temple University-Of The Commonwealth System Of Higher Education	Treatment of osteopetrotic diseases
JP4046349B2 (ja) *	1994-11-07	2008-02-13	ヒューマンジノームサイエンシーズ，インコーポレイテッド	腫瘍壊死因子−γ
EP0727211A1 (de)	1995-02-10	1996-08-21	Smithkline Beecham Corporation	Verwendung von src SH2-spezifische Verbindungen zur Behandlung von Knochenresorptionserkrankungen
IL117175A (en)	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
US7094564B1 (en)	1995-03-15	2006-08-22	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
WO1996028546A1 (en)	1995-03-15	1996-09-19	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
US20030166097A1 (en)	1995-03-15	2003-09-04	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
US5843901A (en)	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
AU6090896A (en)	1995-06-07	1997-01-15	Osteosa Inc.	Osteoclast growth regulatory factor
WO1997000317A1 (en)	1995-06-07	1997-01-03	Osteosa Inc.	Osteoclast growth regulatory factor
ES2253753T3 (es)	1995-06-29	2006-06-01	Immunex Corporation	Citocina que induce apoptosis.
US6613544B1 (en)	1995-12-22	2003-09-02	Amgen Inc.	Osteoprotegerin
US6369027B1 (en)	1995-12-22	2002-04-09	Amgen Inc.	Osteoprotegerin
US6046048A (en)	1996-01-09	2000-04-04	Genetech, Inc.	Apo-2 ligand
US5981220A (en)	1996-03-27	1999-11-09	Human Genome Sciences, Inc.	Epidermal differentiation factor
TW555765B (en) *	1996-07-09	2003-10-01	Amgen Inc	Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
JPH1057071A (ja)	1996-08-19	1998-03-03	Snow Brand Milk Prod Co Ltd	新規ｄｎａ及びそれを用いた蛋白質の製造方法
WO1998025958A2 (en)	1996-12-13	1998-06-18	Schering Corporation	Mammalian cell surface antigens comprising structural motifs characteristic of a member of the tnf ligand family
WO1998028423A2 (en)	1996-12-20	1998-07-02	Board Of Regents, The University Of Texas System	Compositions and methods of use for osteoclast inhibitory factors
FR2757507B1 (fr)	1996-12-20	1999-01-29	Inst Francais Du Petrole	Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation
EP2003203A1 (de)	1996-12-23	2008-12-17	Immunex Corporation	Ligand für den Rezeptorauslöser von NF-kappa b, wobei der Ligand Mitglied der TNF-Überfamilie ist
US6271349B1 (en)	1996-12-23	2001-08-07	Immunex Corporation	Receptor activator of NF-κB
EP2336168A1 (de)	1997-04-15	2011-06-22	Sankyo Company Limited	Neues Protein und Methoe zur Herstellung
US5843678A (en)	1997-04-16	1998-12-01	Amgen Inc.	Osteoprotegerin binding proteins
ATE363533T1 (de)	1997-04-16	2007-06-15	Amgen Inc	Osteoprotegerin bindende proteine und rezeptoren
US6316408B1 (en)	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
CA2229449A1 (en) *	1997-04-25	1998-10-25	Takeda Chemical Industries, Ltd.	Novel receptor protein and its use
JP2002514079A (ja)	1997-05-01	2002-05-14	アムジエン・インコーポレーテツド	キメラｏｐｇポリペプチド
WO1998054201A1 (en)	1997-05-29	1998-12-03	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like protein 8
US6087555A (en)	1997-10-15	2000-07-11	Amgen Inc.	Mice lacking expression of osteoprotegerin
US6790823B1 (en)	1998-04-23	2004-09-14	Amgen Inc.	Compositions and methods for the prevention and treatment of cardiovascular diseases
ATE412746T1 (de)	1998-05-14	2008-11-15	Immunex Corp	Verfahren zur hemmung der wirkung der osteoklasten
CN1318105A (zh)	1998-09-15	2001-10-17	M&E生物技术公司	负调节Osteoprotegerin配体活性的方法
AU6078500A (en)	1999-07-09	2001-01-30	Amgen, Inc.	Combination therapy for conditions leading to bone loss
US20030144187A1 (en)	1999-09-03	2003-07-31	Colin R. Dunstan	Opg fusion protein compositions and methods
CA2349406C (en)	1999-09-03	2011-01-11	Amgen Inc.	Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030103978A1 (en)	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
DE60134459D1 (de)	2000-02-23	2008-07-31	Amgen Inc	Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
US20040247596A1 (en)	2000-08-18	2004-12-09	Odgren Paul R.	TRANCE regulation of chondrocyte differentiation
WO2002024896A2 (en)	2000-09-22	2002-03-28	Immunex Corporation	Screening assays for agonists or antagonists of receptor activat or of nf-kb
EP1399175A4 (de)	2001-05-17	2005-11-30	Immunex Corp	Therapeutische verwendung von rang-antagonisten
MXPA03011270A (es)	2001-06-06	2004-03-18	Immunex Corp	Uso de antagonistas rank para tratar cancer.
MY143582A (en)	2001-06-26	2011-05-31	Amgent Fremont Inc	Antibodies to opgl
US6753755B2 (en) *	2001-06-28	2004-06-22	Safer Home, Inc.	Electrical safety connector fuse
US7084257B2 (en) *	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US6592001B2 (en) *	2001-12-18	2003-07-15	Kimberly-Clark Worldwide	Dispenser for sheet material containing a dispensing port incrementally variable within a range
PL375041A1 (en)	2002-04-05	2005-11-14	Amgen Inc.	Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
US7706431B2 (en) *	2005-06-30	2010-04-27	Nokia Corporation	System and method for providing optimized receiver architectures for combined pilot and data signal tracking

1998
- 1998-04-15 AT AT98918244T patent/ATE363533T1/de active
- 1998-04-15 PL PL98336311A patent/PL190092B1/pl unknown
- 1998-04-15 CA CA2285746A patent/CA2285746C/en not_active Expired - Lifetime
- 1998-04-15 SI SI9830889T patent/SI0975754T2/sl unknown
- 1998-04-15 RO ROA201200577A patent/RO128635A2/ro unknown
- 1998-04-15 DE DE69837845.8T patent/DE69837845T3/de not_active Expired - Lifetime
- 1998-04-15 SK SK1419-99A patent/SK288559B6/sk active Protection Beyond IP Right Term
- 1998-04-15 EE EEP199900611A patent/EE05496B1/xx unknown
- 1998-04-15 DK DK98918244.9T patent/DK0975754T4/en active
- 1998-04-15 ID IDW991225A patent/ID23855A/id unknown
- 1998-04-15 BR BR9808545-0A patent/BR9808545A/pt not_active Application Discontinuation
- 1998-04-15 CN CN98806073A patent/CN1264427A/zh active Pending
- 1998-04-15 IL IL13230498A patent/IL132304A0/xx unknown
- 1998-04-15 EP EP06015956A patent/EP1717315A3/de not_active Withdrawn
- 1998-04-15 WO PCT/US1998/007584 patent/WO1998046751A1/en not_active Ceased
- 1998-04-15 EA EA199900939A patent/EA003636B1/ru not_active IP Right Cessation
- 1998-04-15 CZ CZ0359899A patent/CZ302262B6/cs not_active IP Right Cessation
- 1998-04-15 HU HU0001400A patent/HU230547B1/hu unknown
- 1998-04-15 TR TR1999/02512T patent/TR199902512T2/xx unknown
- 1998-04-15 NZ NZ500253A patent/NZ500253A/xx not_active IP Right Cessation
- 1998-04-15 ES ES98918244.9T patent/ES2284203T5/es not_active Expired - Lifetime
- 1998-04-15 JP JP54425798A patent/JP2001526532A/ja not_active Withdrawn
- 1998-04-15 AU AU71205/98A patent/AU743257B2/en not_active Ceased
- 1998-04-15 EP EP98918244.9A patent/EP0975754B2/de not_active Expired - Lifetime
- 1998-04-16 TW TW087105837A patent/TW589376B/zh not_active IP Right Cessation
1999
- 1999-10-15 NO NO19995044A patent/NO325175B1/no not_active IP Right Cessation
- 1999-10-21 BG BG103824A patent/BG65242B1/bg unknown
2001
- 2001-11-30 AU AU95234/01A patent/AU779461C/en not_active Expired
2005
- 2005-04-27 AU AU2005201799A patent/AU2005201799B2/en not_active Expired
2006
- 2006-01-19 US US11/336,067 patent/US7923008B2/en not_active Expired - Fee Related
2007
- 2007-09-04 JP JP2007228804A patent/JP5001758B2/ja not_active Expired - Lifetime
2008
- 2008-06-05 AU AU2008202516A patent/AU2008202516A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO325175B1 (no)	2008-02-11
CZ302262B6 (cs)	2011-01-19
EP0975754A1 (de)	2000-02-02
IL132304A0 (en)	2001-03-19
US7923008B2 (en)	2011-04-12
BG103824A (en)	2000-05-31
AU9523401A (en)	2002-01-24
ES2284203T5 (es)	2016-03-11
JP2001526532A (ja)	2001-12-18
EP0975754B2 (de)	2016-01-06
BR9808545A (pt)	2000-05-23
NO995044D0 (no)	1999-10-15
NZ500253A (en)	2002-09-27
AU779461C (en)	2005-10-13
US20060246064A1 (en)	2006-11-02
WO1998046751A1 (en)	1998-10-22
AU7120598A (en)	1998-11-11
CZ359899A3 (cs)	2000-02-16
EP1717315A3 (de)	2007-06-20
SI0975754T1 (sl)	2007-10-31
CN1264427A (zh)	2000-08-23
AU2008202516A1 (en)	2008-06-26
SK288559B6 (sk)	2018-05-02
DK0975754T4 (en)	2016-03-21
DK0975754T3 (da)	2007-10-01
AU2005201799B2 (en)	2008-06-12
JP2008054682A (ja)	2008-03-13
DE69837845D1 (de)	2007-07-12
AU779461B2 (en)	2005-01-27
ATE363533T1 (de)	2007-06-15
TR199902512T2 (xx)	2000-06-21
DE69837845T2 (de)	2008-01-31
EA003636B1 (ru)	2003-08-28
CA2285746A1 (en)	1998-10-22
ES2284203T3 (es)	2007-11-01
EA199900939A1 (ru)	2000-08-28
SI0975754T2 (sl)	2016-04-29
NO995044L (no)	1999-12-15
EP0975754B1 (de)	2007-05-30
PL336311A1 (en)	2000-06-19
HUP0001400A2 (en)	2000-07-28
HU230547B1 (hu)	2016-11-28
BG65242B1 (bg)	2007-09-28
RO128635A2 (ro)	2013-07-30
HUP0001400A3 (en)	2001-12-28
DE69837845T3 (de)	2016-06-23
SK141999A3 (en)	2000-05-16
ID23855A (id)	2000-05-25
EP1717315A2 (de)	2006-11-02
EE9900611A (et)	2000-08-15
CA2285746C (en)	2010-09-28
AU743257B2 (en)	2002-01-24
JP5001758B2 (ja)	2012-08-15
TW589376B (en)	2004-06-01
PL190092B1 (pl)	2005-10-31
AU2005201799A1 (en)	2005-05-26
HK1022330A1 (en)	2000-08-04

Publication	Publication Date	Title
EE05496B1 (et)	2011-12-15	Antikeha, mis seob osteoprotegeriini siduvat valku
PT2305715T (pt)	2017-03-02	Anticorpo monoclonal para a proteína de ligação a osteoprotegerina
EP0679093A1 (de)	1995-11-02	Methode zum überbringen von agenzien an zielzellen.
BR9707379A (pt)	1999-04-13	Anticorpo humano isolado ácido nucleico isolado vetor recombinante de expressão célula hospedeira processo para sintetizar um anticorpo humano que se liga á TNF Alfa humano composição farmacéutica processo para inibir á atividade do TNF humano e uso do anticorpo
ATE283916T1 (de)	2004-12-15	Menschliche metabotropische glutamatrezeptor untertype hmglur7 und verwandte dns-verbindungen
UA102988C2 (ru)	2013-09-10	ВЫДЕЛЕННОЕ АНТИТЕЛО ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕН-СВЯЗЫВАЮЩАЯ ЧАСТЬ, КОТОРАЯ СВЯЗЫВАЕТ TNFα ЧЕЛОВЕКА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ, И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, В КОТОРОМ АКТИВНОСТЬ TNFα ЯВЛЯЕТСЯ ВРЕДНОЙ
LU91759I2 (fr)	2011-01-24	Denosumab et ses dérivés pharmaceutique acceptables (PROLIA®)
JP2004501631A5 (de)	2008-08-21
BR9814335A (pt)	2000-10-10	Proteìna, exceto as existentes ao natural, polinucleotìdeo substancialmente puro, anticorpo elaborado por um processo que compreende a etapa de injetar uma preparação farmaceuticamente aceitável, vetor para expressar o drr-1 de rato, vetor, célula hospedeira drr-1 de rato, drr-1 de ser humano, drr-2 de ser humano, drr-3 de ser humano, drr-4 de ser humano, drr-5 de ser humano, drr-6 de ser humano recombinantes, e, processo para ensaiar um composto de teste quanto à sua capacidade para ligar-se a ou para ativar um receptor especìfico de gânglios da raiz dorsal ligado à proteìna g (drr)
WO2001090358A3 (en)	2003-01-23	Mammalian receptor proteins; related reagents and methods
HK1049017A1 (zh)	2003-04-25	人受体蛋白、相关的试剂和方法
WO2001036467A3 (en)	2002-05-10	Mammalian receptor proteins; related reagents and methods
WO1999046379A3 (en)	1999-10-21	Human receptor proteins; related reagents and methods
AU5305300A (en)	2000-12-18	Mammalian receptor proteins; related reagents and methods
WO2001057219A3 (en)	2002-03-07	Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
NZ515382A (en)	2004-03-26	OX2 receptor homologs
ES2082132T3 (es)	1996-03-16	Composicion que contiene al menos dos anticuerpos distintos o fragmentos de ellos.
WO1999019480A3 (en)	1999-06-24	Human receptor proteins; related reagents and methods
Zibirre et al.	1987	Detection and localization of a cytoplasmic domain on the beta-subunit of Na+, K+-ATPase. A monoclonal antibody study.